A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine
Latest Information Update: 07 May 2024
At a glance
- Drugs Avacopan (Primary) ; Azathioprine; Cyclophosphamide; Cyclophosphamide; Mycophenolate; Prednisone; Rituximab
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis with polyangiitis; Microscopic polyangiitis
- Focus Registrational; Therapeutic Use
- Acronyms ADVOCATE
- Sponsors ChemoCentryx
- 01 May 2024 According to an Amgen media release, results of a post-hoc analysis from this trial will be presented at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego.
- 18 Nov 2023 Results of subgroup analysis assessing the safety and efficacy of Avacopan in patients with ANCA-associated vasculitis receiving rituximab published in the Annals of the Rheumatic Diseases.
- 15 Nov 2023 Results of post-hoc analysis assessing effect of avacopan on urinary albumin:creatinine ratio in patients with antineutrophil cytoplasmic autoantibody presented at the ACR Convergence 2023.